/
COO
$71.71+$0.32 (+0.45%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$13.9B
195M shares
52-week range
$58.89 – $89.83
41% from low
Sector
OPHTHALMIC GOODS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-29.04
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.53B | $2.65B | $2.43B | $2.92B | $3.31B | $3.59B | $3.90B | $4.09B |
| Cost of revenue | $900.5M | $896.6M | $896.1M | $966.7M | $1.17B | $1.24B | $1.30B | $1.61B |
| Gross profit | $1.63B | $1.76B | $1.53B | $1.96B | $2.14B | $2.36B | $2.60B | $2.48B |
| Gross margin | 64.4% | 66.2% | 63.1% | 66.9% | 64.7% | 65.6% | 66.6% | 60.7% |
| R&D | $84.8M | $86.7M | $93.3M | $92.7M | $110.3M | $137.4M | $155.1M | $172.2M |
| Operating income | $403.1M | $546.7M | $311.8M | $505.8M | $507.6M | $533.1M | $705.7M | $682.9M |
| EBITDA | $689.7M | $826.2M | $590.4M | $823.9M | $878.7M | $885.9M | $1.07B | $1.05B |
| Net income | $139.9M | $466.7M | $238.4M | $2.94B | $385.8M | $294.2M | $392.3M | $374.9M |
| Net margin | 5.5% | 17.6% | 9.8% | 100.8% | 11.7% | 8.2% | 10.1% | 9.2% |
| EPS (diluted) | 2.81 | 9.32 | 4.81 | 59.07 | 1.94 | 1.48 | 1.96 | 1.87 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4.3B | $4.63 | $4.58–$4.67 | 11 |
| 2027 | $4.5B | $5.01 | $4.91–$5.08 | 11 |
| 2028 | $4.7B | $5.48 | $4.55–$6.21 | 8 |
| 2029 | $5.0B | $5.95 | $5.91–$5.99 | 6 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$59.43
Price
$71.71
Implied downside
-17%
Peer comparison
The Cooper Companies, Inc. Common Stock
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
www.coopercos.com- Employees
- 15,000
- IPO / List date
- Jan 21, 1983
- HQ
- SAN RAMON, CA
Held by traders on TradeandTell
No one on the platform currently holds COO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-12-31 | 117,292 | $10.8M |
| Bridgewater Associatesas of 2026-03-31 | 6,111 | $436.9K |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 0.04% ($0.03/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2023-07-26 | $0.0300 | 2023-08-11 |
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-02-20 | 4-for-1 |
Recent trades on TradeandTell
No one on the platform has traded COO yet.
